China Focus: China pushes forward reforms to expand access to anti-cancer drugs

Source: Xinhua| 2019-02-12 18:46:38|Editor: mmm
Video PlayerClose

BEIJING, Feb. 12 (Xinhua) -- Life-saving anti-cancer drugs, once hard to afford or find on the market by many patients in China, have become accessible for more under the country's reforms in recent years.

A State Council executive meeting chaired by Premier Li Keqiang decided Monday that China will further streamline the registration and approval of new anti-cancer drugs, announcing that experts will be invited to select new overseas drugs to meet urgent clinical needs, and import policies will be improved for a faster launch of the new drugs in China.

These are the most recent efforts to expand access to anti-cancer drugs made by China, which has seen more than 3.5 million new cases of cancer and more than 2 million cancer deaths every year, according to research data released in 2018.

LOWER PRICES

In July last year, the box-office hit "Dying to Survive" sparked heated debate over high prices of anti-cancer drugs in China.

The film is based on the case of a leukemia patient called Lu Yong, who found it hard to afford Gleevec, a patented drug developed by Swiss company Novartis, and managed to buy a much cheaper generic version produced in India for himself and many other patients.

"China has been facilitating the approval of high-quality generic drugs, but most of the targeted cancer drugs used here are still imported ones," Liu Lihong, a senior pharmacist at a Beijing-based hospital, said in an earlier interview with Xinhua, adding that many patients using the expensive imported drugs are faced with high costs.

Shortly after the film was released, 17 anti-cancer drugs were included in China's medical insurance reimbursement list in October 2018, with their prices cut by 56.7 percent on average after a round of price negotiations between the National Healthcare Security Administration (NHSA) and pharmaceutical companies.

For example, the price of Erbitux, a drug produced by German pharmaceutical company Merck to treat rectal cancer, fell from around 4,200 yuan (619 U.S. dollars) a bottle to 1,295 yuan, the China Daily reported.

The NHSA recently announced that China had included 34 drugs that treat major cancers, such as lung, breast, stomach and rectal cancer, in the national basic medical insurance program after price negotiations in the past three years.

"Cancer drugs have been the priority in price negotiations over the past few years," China Daily quoted Shi Lichen, founder of a Beijing-based medical consulting company, as saying. He believes similar price negotiations will become a regular practice.

From May 1, 2018, import tariffs have also been lifted on all common drugs including anti-cancer drugs and anti-cancer alkaloid-based drugs, which could bring about "a drop of at least 20 percent in the prices of imported anti-cancer drugs," according to Shi Luwen, a researcher with Peking University.

QUICKER APPROVAL

In 2018, the National Medical Products Administration (NMPA) approved 48 new drugs, 18 of which are anti-cancer drugs. Other newly approved drugs can be used for treating conditions and side effects connected with cancer, such as vomiting caused by chemotherapy.

A total of 13 of these anti-cancer drugs are imported new drugs, benefiting from the NMPA's efforts to remove the lag of five to eight years between when new anti-cancer drugs are approved abroad and domestically.

Since last year, manufacturers are able to submit the research data obtained overseas for new drug applications as long as their research indicates no racial difference in response to the drugs.

Shi Lichen, founder of the Beijing-based medical consulting company, reckoned that authorities will also stimulate more domestic producers to improve drug research and development.

Clinical drug-trials used to take at least two years to get approved after application, while the NPMA announced last year that trials can be launched in 60 days from the date when the application is accepted, under the prerequisite that the applicants receive no queries or negative feedback.

All these reforms are considered to offer more options to cancer patients in China, where the most common treatment for cancer remains to be chemotherapy.

As the country continues to expand the system regarding evaluation and approval of pharmaceuticals this year, rafts of policies would be implemented to facilitate anti-cancer drug research and approval, including eliminating the requirements for certain overseas new drugs to be approved abroad before applying for import and encouraging parallel development of innovative drugs domestically and overseas.

TOP STORIES
EDITOR’S CHOICE
MOST VIEWED
EXPLORE XINHUANET
010020070750000000000000011100001378158501
百姓彩票 大发app 凤凰彩票app 乐发iv游戏平台 凤凰彩票大厅 乐发彩票 乐发彩票app下载 大发彩票 乐发v官网 乐发lll 乐发lv入口 乐发iv首页 乐发ll登录 凤凰彩票大厅 乐发官网 乐发ii下载入口 乐发ll 乐发v平台 乐发v官网 乐发lll 乐发lv入口 乐发iv首页 乐发ll登录 乐发lv 乐发lll安装 乐发lv 乐发登录入口 乐发iv游戏平台 凤凰彩票登录 网信彩票 彩神 彩神彩票官方网站 彩神彩票官网首页 彩神官方app下载安卓版 凤凰彩票登录 彩神v3 凤凰彩票app下载 彩神官方app下载安卓版 网信快三 一分快3 快三彩票购彩平台 凤凰彩票官方 快3官网 网信彩票 快3app 网信彩票平台 百姓彩票平台 网信平台官网 快3app下载 百姓彩票 每日彩票 快3app 百姓彩票 每日彩票 快3app 百姓彩票平台 幸运5分彩快3 快3彩票app下载 百姓彩票网站网址 大发10分PK10 快3下载 网信彩票平台 网信平台官网 快3彩票官网app 凤凰彩票官方 彩神彩票 大发10分PK10 彩神v3 大发彩票app下载 百姓彩票网站网址 彩神购彩平台 每日彩票 官方正规快三彩票平台 彩神彩票购彩平台 百姓彩票 凤凰彩票购彩平台 凤凰彩票app下载 彩神官方app下载安卓版 网信快三 一分快3 快三彩票购彩平台 凤凰彩票官方 彩神彩票 大发10分PK10 彩神v3 凤凰彩票登录 乐发lv 乐发∨Il 百姓彩票网站网址 乐发彩票 乐发彩票官方网站 乐发lll安装 百姓彩票网站网址 凤凰彩票app下载 大发10分PK10 乐发2 乐发app 凤凰彩票 大发彩票app 乐发登录入口 乐发ll登录 乐发v官网 乐发官网 大发彩票app下载 凤凰彩票购彩平台 彩神彩票 官方正规快三彩票平台 一分快3 百姓彩票网站网址 凤凰彩票app下载 大发10分PK10 乐发2 乐发app 凤凰彩票 大发彩票app 乐发登录入口 乐发ll登录 乐发v官网 乐发官网 大发彩票app下载 凤凰彩票购彩平台 彩神彩票 官方正规快三彩票平台 1分快三平台 百姓彩票平台 凤凰彩票登录 幸运5分彩快3 彩神 乐发彩票 乐发 大发彩票 乐发iv游戏平台 乐发lv 乐发lll 乐发ii下载入口 乐发彩票官方网站 凤凰彩票官方网站 凤凰快3 彩神彩票官网首页 1分快三平台 百姓彩票平台 凤凰彩票登录 幸运5分彩快3 彩神 乐发彩票 乐发 大发彩票 乐发iv游戏平台 乐发lv 凤凰彩票app 乐发app 网信彩票平台 网信彩票平台 乐发iv游戏平台 凤凰彩票app 乐发lv 乐发彩票app下载 凤凰彩票app 网信彩票平台 乐发彩票app下载 乐发lv 乐发app 大发彩票安卓下载 大发彩票安卓下载 大发彩票 乐发彩票app下载 网信彩票平台 乐发iv游戏平台 彩神彩票 乐发彩票中心 极速快3彩票平台 人人快三凤凰 大发彩票app 大发彩票大全 乐发彩票 彩神彩票官方网站 乐发app 酷天堂彩票平台 凤凰彩票app下载 凤凰彩票大厅 凤凰彩票app 极速快3彩票平台 凤凰彩票 凤凰快3 乐发ll官网 乐发彩票中心 正规快三送彩金平台 凤凰彩票官方 乐发ll 乐发 网信彩票 彩神彩票 彩神彩票官方网站 大发彩票app 网信彩票用户 百姓快三 百姓彩票平台 乐发lv 乐发彩票app下载 彩信平台 网信彩票 乐发彩票官方网站 乐发∨Il 人人快三凤凰 凤凰彩票 凤凰快3 乐发ll官网 乐发彩票中心 正规快三送彩金平台 凤凰彩票官方 乐发ll 乐发 网信彩票 彩神彩票 彩神彩票官方网站 人人快三凤凰 乐发彩票 彩神彩票 乐发iv游戏平台 乐发彩票 大发彩票中心 凤凰彩票登录 凤凰彩票app 彩神彩票 大发彩票 乐发ll 大发彩票app 凤凰快3 凤凰彩票 彩神彩票 乐发ll 凤凰彩票 乐发lll 凤凰彩票大厅 网信彩票 彩神彩票 乐发lv 快盈彩票 乐发彩票官方网站 盈彩网投资平台 大发官网 一分时时彩 乐发lv 快3平台 凤凰快3 乐发ll 全民彩票 乐发彩票官方网站 百姓彩票 乐发彩票 大发彩票 极速快3 乐发app 大发官网 乐发lll 快3平台 凤凰快3 乐发ll 全民彩票 乐发彩票官方网站 百姓彩票 乐发彩票 大发彩票 极速快3 乐发app 彩神iv 大发彩票app 大小单双平台 一分pk10 乐发lv 快盈彩票 乐发官网 快彩彩票 百姓彩票 凤凰彩票大厅 网信彩票 乐发彩票中心 网信快3 乐发 彩神xl 三分快3 大发彩票 大发官网 乐发lll 快3平台 凤凰快3 乐发ll 全民彩票 乐发彩票官方网站 百姓彩票 乐发彩票 乐发彩票官方网站 大发彩票 乐发 分分快3 彩神vl 55世纪 55世纪 凤凰快3 乐发彩票 乐发lv welcome凤凰彩票 乐发ll 1分快3 彩神 彩神ll 1分快3官网 1分快3的平台 welcome凤凰彩票 三分快3 彩神x 彩神vl 凤凰彩票 彩神xl 大发彩票 凤凰彩票大厅 乐发官网 乐发ll 乐发lll 乐发lv 大发彩票app 大发彩票 乐发 乐发彩票 乐发彩票中心 凤凰快3 乐发彩票 彩神xl 腾讯快3 大发彩票 彩神xl 大发彩票 乐发彩票 大发彩票app 快3平台 乐发 1分快3 乐发彩票 彩神x 凤凰快3 彩神xl 彩吧助手 大发彩票app 快3平台 大发排列3 彩神iv 彩神vl 乐发IV 彩神x 一分pk10 大发排列3 乐发lv 快3彩票 乐发app下载 三分快3 快三平台助手 乐发彩票ll 彩神iv 乐发lll下载 盈彩网投资平台 乐发Ⅲ 一分pk10 凤凰彩票 乐发Vll 大发官网 乐发ll 大发彩票 乐发1 凤凰快3 彩神vl 乐发lx 百姓彩票 乐发VI 彩神x 乐发IV 极速快3 乐发 凤凰快3 网信快3 乐发lv 快3彩票 乐发app下载 三分快3 快三平台助手 乐发彩票ll 彩神iv 乐发lll下载 盈彩网投资平台 乐发Ⅲ 凤凰彩票大厅 乐发lv 乐发lv 乐发lv 凤凰彩票 大发彩票 大发彩票 凤凰彩票 乐发lv 凤凰彩票 凤凰彩票 乐发lv 乐发ll 凤凰彩票app下载 凤凰彩票 凤凰彩票 乐发lv 乐发ll 凤凰彩票app下载 凤凰彩票 凤凰彩票 乐发lv 彩神x 乐发 乐发ll 极速快3 乐发lv 乐发彩票中心 快3彩票 凤凰彩票大厅 彩神x 凤凰彩票app 分分快3 网信彩票 网盟彩票 凤凰彩票 百姓彩票 乐发 快彩彩票 乐发彩票 快3平台 百姓彩票 大小单双平台 凤凰快3 彩神xl 一分pk10 乐发lv 三分快3 大发彩票 乐发彩票 快3平台 百姓彩票 大小单双平台 凤凰快3 彩神xl 一分pk10 乐发lv 三分快3 大发彩票 极速快3 乐发ll 网信彩票 乐发lv 全民彩票 凤凰彩票app下载 快盈彩票 大发彩票app 大发官网 凤凰彩票 彩神iv 大发彩票 网信快3 凤凰彩票 百姓彩票